Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Development and validation of the irritable bowel syndrome satisfaction with care scale.

Dorn SD, Morris CB, Schneck SE, Hopper TM, Hu YJ, Kelapure R, Weinland SR, Norton WF, Norton NJ, Drossman DA.

Clin Gastroenterol Hepatol. 2011 Dec;9(12):1065-71.e1-2. doi: 10.1016/j.cgh.2011.08.009. Epub 2011 Aug 18.

PMID:
21854738
2.

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M.

Mol Cancer Ther. 2007 Jul;6(7):2012-21.

3.

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.

Dev IK, Dornsife RE, Hopper TM, Onori JA, Miller CG, Harrington LE, Dold KM, Mullin RJ, Johnson JH, Crosby RM, Truesdale AT, Epperly AH, Hinkle KW, Cheung M, Stafford JA, Luttrell DK, Kumar R.

Br J Cancer. 2004 Oct 4;91(7):1391-8.

Supplemental Content

Loading ...
Support Center